David Wells, a board member at Hims & Hers Health (HIMS), acquired 48,400 shares this Tuesday, paying between $24.19 and $24.25 per share in a transaction totaling approximately $1.2 million. This purchase increased his holdings to 224,400 shares and represents his first acquisition on the open market since August 2021.
Hims & Hers Health, Inc., HIMS
The market responded positively to the announcement. HIMS stock surged approximately 6.8% to reach $25.46 during the trading session following the filing disclosure, with market participants interpreting the insider transaction as a bullish signal.
Wells, who previously held the position of Chief Financial Officer at Netflix and joined the Hims board in 2020, had exclusively been divesting shares in recent periods — disposing of 260,000 shares during February 2024 and an additional 40,000 in November of that year. His decision to switch from seller to buyer after nearly half a decade caught the attention of market observers.
Shares of HIMS have tumbled more than 21% year-to-date, dramatically underperforming the S&P 500’s 9.9% appreciation. This performance gap highlights the company’s current difficulties.
Earlier this month, the stock experienced a sharp 14% decline following the release of first-quarter financial results that fell short of analyst projections. The telehealth provider reported a quarterly deficit and revenues that failed to meet Wall Street’s forecasts — disappointing outcomes for stakeholders.
A major headwind for investors has been the evolution of the company’s GLP-1 medication segment. During periods when branded weight-loss pharmaceuticals from Novo Nordisk and Eli Lilly faced supply constraints, Hims experienced rapid expansion by providing more affordable compounded alternatives. However, with supply chains now normalized, these pharmaceutical giants are recapturing their market position.
This past March, Hims announced a partnership to distribute Novo’s branded weight-loss pharmaceutical products directly via its digital platform, substituting the compounded formulations it had previously provided. Subsequently, in April, the company expanded its platform capabilities to enable healthcare providers to issue prescriptions fulfilled through independent pharmacy networks, including LillyDirect.
This represents a substantial strategic transformation. Compounded GLP-1 treatments had evolved into a fundamental component of how Hims differentiated itself to consumers and the investment community. Sustaining revenue momentum while navigating this transition represents the company’s current operational hurdle.
Separately, Wells was granted 957 restricted stock units on May 20, consistent with routine director compensation structures.
As of Wednesday’s market close, HIMS was valued at $25.46, reflecting a 6.8% gain on the day the purchase disclosure became public.
The post Hims & Hers Health (HIMS) Stock Surges 6.8% Following Board Member’s $1.2 Million Share Purchase appeared first on Blockonomi.
